Cord Blood Stemcell Technology and Processing

Cordlife uses the most advanced fully automated Sepax®2 technology for processing the cord blood.

Stem cell isolation is a critical step in cord blood banking. It affects the number of stem cells that can be harvested or recovered from the cord blood. Cell recovery rates are critical because a higher number and better Quality of stem cells could enhance the success of the transplant or treatment. That’s why Cordlife has invested in the Sepax®2 automated stem cell processing technology, a safe, sterile and fully automated cord blood processing technology – so you get adequate and potent stem cells for maximum transplant success*.


The first private cord blood bank in Singapore to offer the Sepax®2 automated processing technology, a Swiss-made and U.S. FDA-cleared Personalized Processing Instrument which can recover as high as 99.46%[1] of Total Nucleated Cells (TNC) from cord blood; up to 57%[2] higher cell count than other processing methods. It is also a functionally closed processing system which ensures the sterility of the cord blood by eliminating exposure to air contaminants and also cross contamination.

Sepax®2 Stem Cell Technology

Feature Benefits to You

  • Swiss-made patented automated cord blood processing system
  • Advanced technology with new protocols
  • We process your baby’s cord blood with high Swiss precision, reliable, state-of-the-art technology.
    Fully Automated

  • Requires no external centrifuge or operator intervention during processing
  • Controlled, smooth and precise cell separation by an advanced optical sensor.
  • The yield from cord blood processing is consistent, with reproducible higher results (that is, cell recoveries).
    Cell Recovery

  • Able to achieve as high as 99%[1] Total Nucleated Cells (TNC) recovery rate

  • More cells are recovered / harvested from your baby’s cord blood for future stem cell treatment (if needed), allowing better chance of a successful transplant.

  • Closed personalized processing system
  • Every baby’s cord blood unit is fully monitored and traceable throughout each procedure
  • Possesses a troubleshooting system. Even in cases of power failure, all cord blood units can be processed without having errors and cross contamination.
  • Processing of your baby’s cord blood unit is safe and highly sterile, leaving zero opportunity for error.

  • The only personalized cord blood processing technology that processes one cord blood unit at a time
  • Sepax®2 is calibrated and tested before every procedure, treating every cord blood unit like its first one as unique as it really is.
  • Uniquely adapted to the qualities of each and every baby’s stem cells, customizing every process accordingly
  • Prevent any sample mix-up and eliminates any possible cross-contamination of your baby’s precious cord blood unit.
    Regulatory Approvals

  • Cleared by U.S. FDA, approved by European Union (evidenced by CE Mark), and Japan MHLW (Ministry of Health and Labor Welfare)
  • Complies with the highest quality standards such as AABB & FACT-Netcord[3]
  • Meets international health, safety and environmental requirements to ensure consumer safety.

  • An advanced cord blood processing technology with proven transplant track record
  • World’s most tried and trusted automated system
  • Over 1 million cord blood units [3] have been processed by the Sepax® System in over 50 countries, this is almost half of the worldwide processing procedures for cord blood inventory.
  • Trusted by majority of the world’s leading public and private cord blood banks
  • The Sepax® system has been chosen by over 75% of the Netcord organizations that group the leading public cord blood banks around the world.
  • Proven technology, equipment and consumables that are used by industry leader – the true validation on the quality of the Sepax® automated processing technology.
    First Bank

  • Cordlife is the first private cord blood bank in India to offer automated cord blood processing with Sepax®2.

  • Our investment in advanced technology now and in the future means you and your family will benefit from any future technological upgrade for the long-term storage of your baby’s stem cells

1. Cordlife umbilical cord blood processing data as at 30 April 2013
2. Valeri et al., Transfusion 1996;36:303-8
3. Biosafe, manufacturer of Sepax® (figures accurate as of 31 March 2013)

ShareShare on Facebook0Tweet about this on TwitterShare on Google+0Share on LinkedIn0Email this to someone

You might also interest